Bevacizumab-Related Gastrointestinal Perforation in Hepatocellular Carcinoma Patient: A Case Report
<p>Introduction: Atezolizumab plus bevacizumab is widely recognized as the first-line treatment for advanced hepatocellular carcinoma (HCC). Bevacizumab, an anti-vascular endothelial growth factor (anti-VEGF), is effective against various cancers but carries a rare risk of gastrointestina...
সংরক্ষণ করুন:
| প্রধান লেখক: | , , , |
|---|---|
| বিন্যাস: | Artigo |
| ভাষা: | Inglês |
| প্রকাশিত: |
Karger Publishers
2025-12-01
|
| মালা: | Case Reports in Oncology |
| অনলাইন ব্যবহার করুন: | https://karger.com/article/doi/10.1159/000549176 |
| ট্যাগগুলো: |
কোনো ট্যাগ নেই, প্রথমজন হিসাবে ট্যাগ করুন!
|